The U.S. Launch of Neupro® for the Treatment of Early-Stage Parkinson's Disease

UCB and SCHWARZ PHARMA announced today that Neupro® (Rotigotine Transdermal System), a new once-daily transdermal dopamine agonist approved for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's disease, is now commercially available in retail pharmacies throughout the United States. Neupro® will be co-promoted by UCB and SCHWARZ PHARMA. These companies have dedicated sales forces that will immediately begin reaching out to physicians who treat Parkinson's disease nationwide.

In conjunction with the U.S. launch, the companies are also kicking off PDAware, a public education campaign which aims to raise the profile of Parkinson's disease. The campaign will highlight the experiences and personal achievements of Parkinson's patients in order to increase understanding of the disease and highlight the latest treatment options, including Neupro®.

"Disabling Parkinson's symptoms can be well controlled with available medications, but may return as the effects of Parkinson's disease medications wear off," said C. Warren Olanow, M.D., Professor and Chair of Neurology, and Professor of Neuroscience at the Mount Sinai School of Medicine in New York City. "Neupro® is the first transdermal or patch formulation available for the treatment of Parkinson’s disease. It provides continuous drug delivery for 24 hours, throughout the day and night. As a new treatment option for early-stage Parkinson's patients, the Neupro® patch helps control symptoms with once-daily dosing."

The U.S. Food and Drug Administration (FDA) approved Neupro® on May 9, 2007 based on results from 15 multinational clinical trials, which involved more than 1,500 patients with Parkinson’s disease. The clinical trials demonstrated that Neupro® was efficacious and generally well-tolerated for early-stage Parkinson's disease, with a low potential for drug-drug interactions. Neupro® is currently available in the United States in three strengths: 2 mg/24 hours; 4 mg/24 hours; and 6 mg/24 hours.

"The FDA's approval of Neupro® as a therapy for many Parkinson's disease patients is a momentous achievement for our company," said Rich Denness, Chief Executive Officer of SCHWARZ PHARMA Inc., USA. "We are proud to offer an effective treatment that controls the symptoms of early-stage Parkinson's disease by providing stable, continuous delivery of medication over a 24-hour period. We are excited to continue working with physicians and their patients who have Parkinson's disease, and we remain committed to educating the Parkinson's community about this new therapy."

About Neupro®
Neupro®, with the active ingredient rotigotine, is a non-ergolinic dopamine receptor-agonist formulated as a transdermal delivery system, a patch, designed for once-a-day application. Neupro® is designed to mimic the action of dopamine, a naturally-produced neurotransmitter crucial for proper motor functioning. The system is applied to the skin once a day and provides rotigotine continuously to the body for 24 hours. Patients receiving Neupro® initiate treatment with a 2 mg/24 hours patch and titrate in 2 mg/24 hours increments each week until the optimal effect is observed. The administration of rotigotine transdermal system offers simple, once-daily dosing, and it is easy to use.

Rotigotine transdermal system is approved in Europe for the treatment of patients with early and advanced Parkinson’s disease in combination with levodopa. Since March 2006, the drug has been available on the European market and has been launched by SCHWARZ PHARMA AG in 14 countries within Europe, including Germany, the UK, Austria, Denmark, Ireland, Norway, Switzerland, Sweden, Greece, Spain, Finland, Poland, Slovakia and the Czech Republic.

Most Popular Now

Lilly and Lycia Therapeutics enter into strategic …

Eli Lilly and Company (NYSE: LLY) and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement focused on the discovery, devel...

SK bioscience and GSK start Phase 3 trial of adjuv…

SK bioscience (SK) and GlaxoSmithKline plc (GSK) today announced the initiation of a Phase 3 clinical study of SK's COVID-19 vaccine candidate, GBP510, in combination wit...

Blood vessels produce growth factor that promotes …

Blood vessels supply tumors with nutrients and, on the other hand, enable cancer cells to spread throughout the body. The settlement of circulating tumor cells in a dista...

No serious health effects linked to mRNA COVID-19 …

Federal and Kaiser Permanente researchers combing the health records of 6.2 million patients found no serious health effects that could be linked to the 2 mRNA COVID-19 v...

New study examines 'Achilles heel' of cancer tumou…

Researchers at the University of British Columbia's faculty of medicine and BC Cancer Research Institute have uncovered a weakness in a key enzyme that solid tumour cance...

AI algorithm solves structural biology challenges

Determining the 3D shapes of biological molecules is one of the hardest problems in modern biology and medical discovery. Companies and research institutions often spend ...

First-in-human clinical trial for a vaccine to tre…

The first patients have been enrolled in a phase 1 randomized placebo-controlled clinical trial to study a therapeutic vaccine for opioid use disorder developed by resear...

A drug costing less than €2 a day helps in the tre…

Metoprolol, a drug widely used to treat cardiovascular disease, is beneficial when administered to COVID-19patients. This is the finding of a study by investigators at th...

Rheumatoid arthritis treated with implanted cells …

With a goal of developing rheumatoid arthritis therapies with minimal side effects, researchers at Washington University School of Medicine in St. Louis have genetically ...

Sandoz strengthens pipeline by entering into agree…

Sandoz, a Novartis division, today announced that it has entered into a commercialization agreement with Bio-Thera Solutions, Ltd. for biosimilar bevacizumab (BAT1706). B...

Pfizer and BioNTech submit a variation to EMA with…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that they submitted a variation to the European Medicines Agency (EMA) requesting to update the Condition...

One in three Americans had COVID-19 by the end of …

A new study published in the journal Nature estimates that 103 million Americans, or 31 percent of the U.S. population, had been infected with SARS-CoV-2 by the end of 20...